[Chemotherapy combining vindesine, thiotepa and methotrexate in metastatic breast cancer after failure of a combination containing anthracycline. Results of a prospective phase II trial].
Twenty-six patients with metastatic breast cancer where treated, after failure of a first line chemotherapy including an anthracycline, with a second line combination of vindesine, methotrexate and thiotepa. Overall tolerance of this treatment was good. There were one complete response and two partial responses. The authors conclude that this treatment has a marginal activity.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D013852:Thiotepa / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D013852:Thiotepa; D014751:Vindesine; D008727:Methotrexate
Chimiothérapie associant vindésine, thiotépa et méthotrexate dans les cancers du sein métastatiques après échec d'une combinaison incluant une anthracycline. Résultats d'un essai phase ii prospectif.